HMGB1 and neoplasm: The NanoTAC (+L) group presented markedly greater percentages of surface CRT-expressing tumor cells (CD45−CRT+), accompanied by substantial extracellular release of HMGB1 and HSP70 (Fig. 5a and Supplementary Fig. 29).